The importance of plasma protein and tissue binding in a drug discovery program to successfully deliver a preclinical candidate.

Hann, Elizabeth; Malagu, Karine; Stott, Andrew; Vater, Huw

Hann, Elizabeth; Malagu, Karine; Stott, Andrew; Vater, Huw.

Afiliación

Hann E; Charles River Laboratories, Robinson Building, Chesterford Research Park, Saffron Walden, United Kingdom. Electronic address: elizabeth.hann@crl.com.
Malagu K; Charles River Laboratories, Robinson Building, Chesterford Research Park, Saffron Walden, United Kingdom.
Stott A; Charles River Laboratories, Robinson Building, Chesterford Research Park, Saffron Walden, United Kingdom.
Vater H; Charles River Laboratories, Robinson Building, Chesterford Research Park, Saffron Walden, United Kingdom.

Prog Med Chem ; 61: 163-214, 2022.

Article en En | MEDLINE | ID: mdl-35753715

Asunto(s)

Proteínas Sanguíneas; Descubrimiento de Drogas; Proteínas Sanguíneas/metabolismo; Unión Proteica

Palabras clave

Albumin; CNS; Drug discovery; Equilibrium dialysis; Fraction unbound; Free drug hypothesis; K(puu); Neurology; PK/PD; Pharmacodynamics; Pharmacokinetics; Plasma protein binding; Therapeutic index; Tissue binding; Tissue distribution; α-1-Acid glycoprotein

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteínas Sanguíneas / Descubrimiento de Drogas Idioma: En Revista: Prog Med Chem Año: 2022 Tipo del documento: Article Pais de publicación: Países Bajos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google